On Friday, Ocular Therapeutix Inc (NASDAQ: OCUL) opened higher 4.79% from the last session, before settling in for the closing price of $9.18. Price fluctuations for OCUL have ranged from $3.24 to $11.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 121.20% annually for the last half of the decade. Company’s average yearly earnings per share was noted -16.28% at the time writing. With a float of $135.46 million, this company’s outstanding shares have now reached $156.65 million.
In an organization with 267 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 90.58%, operating margin of -230.12%, and the pretax margin is -284.02%.
Ocular Therapeutix Inc (OCUL) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ocular Therapeutix Inc is 13.84%, while institutional ownership is 77.39%. The most recent insider transaction that took place on Nov 25 ’24, was worth 26,561. In this transaction Chief Scientific Officer of this company sold 2,948 shares at a rate of $9.01, taking the stock ownership to the 269,059 shares. Before that another transaction happened on Nov 25 ’24, when Company’s Chief Development Officer sold 2,897 for $9.01, making the entire transaction worth $26,102. This insider now owns 213,087 shares in total.
Ocular Therapeutix Inc (OCUL) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -16.28% per share during the next fiscal year.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Check out the current performance indicators for Ocular Therapeutix Inc (OCUL). In the past quarter, the stock posted a quick ratio of 12.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 25.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.06 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Let’s dig in a bit further. During the last 5-days, its volume was 0.94 million. That was inferior than the volume of 1.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 53.75%. Additionally, its Average True Range was 0.55.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 55.43%, which indicates a significant decrease from 69.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.21% in the past 14 days, which was higher than the 54.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.03, while its 200-day Moving Average is $8.24. However, in the short run, Ocular Therapeutix Inc’s stock first resistance to watch stands at $9.78. Second resistance stands at $9.93. The third major resistance level sits at $10.20. If the price goes on to break the first support level at $9.36, it is likely to go to the next support level at $9.09. Assuming the price breaks the second support level, the third support level stands at $8.94.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
There are currently 157,217K shares outstanding in the company with a market cap of 1.58 billion. Presently, the company’s annual sales total 58,440 K according to its annual income of -80,740 K. Last quarter, the company’s sales amounted to 15,430 K and its income totaled -36,490 K.
